QR-Code

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

Introduction: FLT3-ITD mutations occur in approximately 25% of patients with acute myeloid leukemia (AML) and are associated with poor prognosis. Despite initial efficacy, short duration of response and high relapse rates limit clinical use of selective FLT3 inhibitors. Combination approaches with o...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Douglas D. Fang, Hengrui Zhu, Qiuqiong Tang, Guangfeng Wang, Ping Min, Qixin Wang, Na Li, Dajun Yang, Yifan Zhai
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2022-01-01
Schriftenreihe:Translational Oncology
Schlagworte:
FLT3-ITD
BCL-2
HQP1351
APG-2575
Acute myeloid leukemia
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S1936523321002369
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge